Novo stock drops 15% as obesity drug falls short in key trial - Invezz# Novo stock drops 15% as obesity drug falls short in key trial[Health & pharma]Author[Utkarsh Roshan]Feb 23, 2026, 10:45 AM- Investors remain focused on obesity drug performance.- The trial miss sent Novo shares sharply lower.- Novo's CagriSema delivered less weight loss than Lilly's tirzepatide.Shares of Novo Nordisk fell sharply after the company said its next-generation obesity drug CagriSema delivered weaker weight-loss results than ...

Core Viewpoint - Shares of the Danish drugmaker fell sharply after the announcement that its CagriSema experimental obesity drug did not outperform Eli Lilly's Zepbound in a head-to-head clinical trial [1] Group 1 - The CagriSema drug is aimed at obesity treatment and was expected to compete with Eli Lilly's Zepbound [1] - The clinical trial results indicated that CagriSema failed to deliver better weight loss results compared to Zepbound [1] - The market reaction was negative, leading to a significant drop in the company's share price following the news [1]

本文源自：金融界AI电报 诺和诺德欧股股价下跌11%。公司表示，在试验中，其CagriSema的效果不及礼来的Zepbound。 ...

Core Viewpoint - Novo Nordisk shares faced pressure due to a head-to-head study indicating that its drug in development was less effective in weight loss compared to a product from Eli Lilly [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company currently experiencing challenges with its drug development [1] - The company's recent study results have raised concerns about its competitive position in the market against Eli Lilly [1] Industry Summary - The pharmaceutical industry is witnessing intense competition, particularly in the weight loss drug segment, where efficacy is a critical factor for market success [1] - Eli Lilly's product has set a benchmark that other companies, including Novo Nordisk, must meet or exceed to remain competitive [1]

Core Viewpoint - Novo Nordisk's stock experienced a decline of over 10% following the announcement that its next-generation weight loss drug, CagriSema, did not meet its primary target of non-inferiority in weight loss compared to Eli Lilly's drug, tirzepatide, after 84 weeks [1] Group 1 - CagriSema failed to achieve its primary endpoint in the clinical trial [1] - Eli Lilly's stock saw an increase of 2.1% in premarket trading as a result of Novo Nordisk's announcement [1] - Novo Nordisk is considering additional trials for CagriSema, including testing higher-dose combinations [1]

格隆汇2月23日｜在CagriSema数据公布后，诺和诺德盘前下跌11%。消息面上，诺和诺德表示，在试验 中CagriSema的效果不及礼来的Zepbound。 ...

Group 1 - Novo Nordisk's experimental obesity drug CagriSema did not meet the primary endpoint in a trial aimed at demonstrating non-inferiority to Eli Lilly's Tirzepatide in terms of body weight reduction [1] - The trial results indicate a setback for Novo Nordisk in the competitive obesity drug market, where Eli Lilly's Tirzepatide has shown strong performance [1] - This development may impact Novo Nordisk's market position and future growth prospects in the obesity treatment sector [1]

Rolls-Royce share price targets 1,500p ahead of earnings and buyback - Invezz# Rolls-Royce share price targets 1,500p ahead of earnings and buyback[Europe]Author[Crispus Nyaga]Feb 23, 2026, 09:22 AM- The company will also announce strong financial results.- Sky News reported that the company will announce a new buyback this week.- Rolls-Royce stock price surged to a record high this month.Rolls-Royce share price continued soaring last week and reached a record high as market participants waited for its fina ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1: Clinical Trial Results - Eli Lilly's TOGETHER-PsO trial showed that 27.1% of participants receiving Taltz and Zepbound achieved complete skin clearance and at least 10% weight loss, compared to 5.8% for Taltz alone, meeting the primary endpoint [2] - The combination of Taltz and Zepbound resulted in a 40% relative increase in the proportion of patients achieving PASI 100 compared to Taltz monotherapy (40.6% vs. 29%) [2] Group 2: Licensing Agreement - CSL Limited entered into an exclusive licensing agreement with Eli Lilly for the development and commercialization of clazakizumab, with an upfront payment of $100 million and potential milestone payments and royalties on global net sales [4] - CSL retains exclusive rights to develop clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Lilly will explore additional indications [5] Group 3: Stock Performance - The stock is currently trading 2.7% below its 20-day simple moving average and 3.2% below its 50-day simple moving average, indicating short-term weakness, but remains 4.3% above its 100-day simple moving average and 17.6% above its 200-day simple moving average, suggesting longer-term strength [7] - The RSI is at 48.22, indicating neutral territory, while the MACD shows bearish pressure with a value of -5.0984 below its signal line of -3.9365 [8]